Hanna Karvonen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6135331/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. Molecular Cell, 2020, 79, 390-405.e7.	9.7	56
2	Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting. Oncogene, 2019, 38, 3288-3300.	5.9	39
3	Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. Cell Death and Disease, 2020, 11, 790.	6.3	38
4	Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways. Cells, 2019, 8, 812.	4.1	30
5	Targeting ROR1 identifies new treatment strategies in hematological cancers. Biochemical Society Transactions, 2017, 45, 457-464.	3.4	28
6	Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. Blood Advances, 2017, 1, 2257-2268.	5.2	25
7	Targeting Wnt signaling pseudokinases in hematological cancers. European Journal of Haematology, 2018, 101, 457-465.	2.2	13
8	Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors. Cancers, 2021, 13, 3727.	3.7	13
9	Interaction between <scp>ROR</scp> 1 and Mu <scp>SK</scp> activation complex in myogenic cells. FEBS Letters, 2018, 592, 434-445.	2.8	8
10	New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome. Cellular and Molecular Life Sciences, 2022, 79, 276.	5.4	4
11	Cellular thermal shift assay (CETSA) for determining the drug binding affinity using Ba/F3 clones stably expressing receptor pseudokinases. Methods in Enzymology, 2022, 667, 339-363.	1.0	2
12	Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. FASEB Journal, 2021, 35, .	0.5	0